Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 441-447

  Aktas, Bahriye ^a   Kasimir Bauer, Sabine ^a   Lehmann, Nils ^a   Kimmig, Rainer ^a   Tewes, Mitra ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Bisphosphonate; Bone marker; Metastatic breast cancer; Therapy monitoring

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTHRACYCLINE DERIVATIVE; CA 15-3 ANTIGEN; CAPECITABINE; CARBOXY TERMINAL TELOPEPTIDE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; NAVELBINE; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; MUCIN-1; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84878170750     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2409     Document Type: Article

References (31)

1. Plebani M, Bernardi D, Zanninotto M, De Paoli M, Secchiero S and Sciacovelli L: New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem 29: 67-72, 1996. (Pubitemid 26073102)
2. Rosenthal DI: Radiologic diagnosis of bone metastases. Cancer 80: 1595-1607, 1997.
3. Jung K, Lein M, Stephan C, Von HK, Semjonow A and Sinha P: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783-791, 2004. (Pubitemid 39062904)
4. O'Sullivan JM and Cook GJ: A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 46: 152-159, 2002.
5. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, Moura MC and Lipton A: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002. (Pubitemid 34111395)
6. Lipton A, Costa L, Ali S and Demers L: Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28 (4 Suppl 11): 54-59, 2001. (Pubitemid 32844930)
7. Green JR: Bisphosphonates: preclinical review. Oncologist 9 (Suppl 4): 3-13, 2004.
8. Coleman RE: The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94: 2521-2533, 2001.
9. Roodman GD: Mechanisms of bone metastases. N Engl J Med 350: 1655-1664, 2004.
10. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL and Seaman JJ: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 98: 1735-1744, 2003.
11. Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J, Vinholes J, Goas A, Zheng M and for the Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882, 2004. (Pubitemid 38807610)
12. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, et al: The diagnostic value of pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103, 1995.
13. Vogel CL, Schoenfelder J, Shemano I, Hayes DF and Gams RA: Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13: 1123-1128, 1995.
14. Pollen JF, Witztum KF and Ashburn WL: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 142: 773-776, 1984. (Pubitemid 14166610)
15. Huang Q and Ouyang X: Biochemical-markers for the diagnosis of bone metastasis: a clinical review. Cancer Epidemiol 6: 94-98, 2011.
16. Seibel MJ: Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2: 504-517, 2005.
17. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R and Major P: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34: 629-639, 2008.
18. Seibel MJ: The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol 68: 839-849, 2008.
19. Cremers S and Garnero P: Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66: 2031-2058, 2006. (Pubitemid 46372356)
20. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ and Colemann RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59-69, 2005.
21. Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K and Lüftner D: The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27: 1853-1862, 2007. (Pubitemid 46954687)
22. Costa L, Demers LM, Speicher T, Gouveia Curley E, Harvey H, et al: Biochemical markers of bone turnover correlate with the extent of metastatic bone disease. American Society of Clinical Oncology 35th Annual Meeting, Philadelphia, 1999.
23. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, Cerutti S, Frezet MM, Stivanello M, Sacchetto G and Angeli A: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45: 1240-1247, 1999. (Pubitemid 29424263)
24. Demers LM: Biochemical markers in the management of patients with metastatic bone disease. Clin Chem 45: 1131-1132, 1999.
25. Ikeda I, Miura T and Kondo I: Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 77: 102-106, 1996.
26. Costa L, Demers LM, Gouveia A, Schalla J, Costa EB, Demoura MC and Lipton A: Correlation of urinary N-telopeptide levels with progression of bone metastases: a prospective study (Abstract 12). Cancer 88 (Suppl): 3094, 2000.
27. Zafeirakis A: Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer. Hippokratia 14: 164-169, 2010.
28. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE and Coleman RE: Normalization of bone markers is associated with improved survival and elevated bone resorption receiving zoledronic acid. Cancer 113: 193-201, 2008. (Pubitemid 351976401)
29. Pons-Anicet DMF, Krebs BP, Mira R and Namer M: Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer 55: 567-569, 1987. (Pubitemid 17098869)
30. Yildiz M, Oral B, Bozkurt M and Cobaner A: Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 18: 501-505, 2004. (Pubitemid 39410250)
31. Buamah PK, Bent DJ, Bodger WAH and Skillen AW: A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and γ-glutamyl transferase levels in patients with breast cancer. J Surg Oncol 53: 84-87, 1993. (Pubitemid 23164592)